Table 2 Responses on different Disease-related aspects of hMPV per study group
Variables | Community pharmacists | Clinical pharmacists | General practitioners | P-value |
|---|---|---|---|---|
Disease nature | ||||
Viral | 253 (93.0%) | 214 (96.4%) | 205 (94.9%) | 0.135 |
Bacterial | 12 (4.4%) | 8 (3.6%) | 9 (4.2%) | |
Parasitic | 7 (2.6%) | 0 | 2 (0.9%) | |
Incubation period | ||||
5–13 and up to 21 days | 127 (46.7%) | 124 (55.9%) | 111 (51.4%) | 0.043 |
More or less | 24 (8.8%) | 18 (8.1%) | 7 (3.2%) | |
Unable to identify | 121 (44.5%) | 80 (36.0%) | 98 (45.4%) | |
Disease symptoms | ||||
Lymphadenopathy | 210 (77.2%) | 176 (79.3%) | 171 (79.2%) | 0.563 |
Fever | 144 (52.9%) | 111 (50%) | 104 (48.1%) | |
Flu-like symptoms | 215 (79.0%) | 180 (81.1%) | 175 (81.0%) | |
Smallpox like symptoms | 228 (83.8%) | 190 (85.6%) | 184 (85.2%) | |
Identify skin lesions | ||||
Rash | 133 (48.9%) | 118 (53.2%) | 96 (44.4%) | 0.416 |
Papule | 83 (30.5%) | 70 (31.5%) | 79 (36.6%) | |
Vesicle | 125 (45.9%) | 98 (44.1%) | 116 (53.7%) | |
Pustule | 22 (8.1%) | 19 (8.6%) | 32 (14.8%) | |
Unable to identify | 65 (23.9%) | 40 (18.0%) | 41 (18.9%) | |
Disease transmission | ||||
Direct contact with a patient | 211 (77.6%) | 149 (67.1%) | 166 (76.9%) | 0.104 |
Contact with infected body fluids | 91 (33.5%) | 79 (35.6%) | 88 (40.7%) | |
Sexual transmission | 76 (28.0%) | 71 (32.0%) | 71 (32.9%) | |
Airborne/droplets | 88 (32.4%) | 81 (36.5%) | 60 (27.8%) | |